Ligand Pharmaceuticals Incorporated (LGND) Insider Trading
- $5,095,853.39
- $210,833,691.85
- March 5, 2024
- John L Higgins
| Trader Name | Date | Title | Amount | Price | Type | Total Value |
|---|---|---|---|---|---|---|
| Oct. 1, 2018 | COO | 12,000 | $273.88 | Sell | $3,286,560.00 | |
| Sept. 17, 2018 | SVP | 2,813 | $250.69 | Sell | $705,190.97 | |
| Sept. 4, 2018 | SVP | 19,417 | $254.99 | Sell | $4,951,140.83 | |
| Sept. 4, 2018 | Insider | 12,000 | $255.01 | Sell | $3,060,120.00 | |
| Sept. 4, 2018 | Director | 3,335 | $254.96 | Sell | $850,291.60 | |
| Aug. 30, 2018 | CEO | 3,500 | $258.25 | Sell | $903,875.00 | |
| Aug. 29, 2018 | EVP | 18,357 | $256.69 | Sell | $4,712,058.33 | |
| Aug. 17, 2018 | CEO | 34,500 | $241.96 | Sell | $8,347,620.00 | |
| Aug. 17, 2018 | Director | 9,000 | $239.78 | Sell | $2,158,020.00 | |
| July 2, 2018 | Director | 2,500 | $207.48 | Sell | $518,700.00 | |
| June 4, 2018 | Director | 4,000 | $194.51 | Sell | $778,040.00 | |
| May 15, 2018 | CEO | 12,405 | $179.97 | Sell | $2,232,527.85 | |
| May 10, 2018 | Insider | 8,881 | $167.63 | Sell | $1,488,722.03 | |
| April 2, 2018 | Director | 2,500 | $160.43 | Sell | $401,075.00 | |
| March 12, 2018 | Director | 622 | $180.73 | Sell | $112,414.06 | |
| March 9, 2018 | Director | 7,500 | $175.73 | Sell | $1,317,975.00 | |
| March 5, 2018 | Director | 3,335 | $160.90 | Sell | $536,601.50 | |
| Feb. 27, 2018 | Director | 17,170 | $152.37 | Sell | $2,616,192.90 | |
| Feb. 23, 2018 | Director | 3,417 | $155.00 | Sell | $529,635.00 | |
| Feb. 23, 2018 | COO | 5,444 | $152.98 | Sell | $832,823.12 | |
| Feb. 15, 2018 | CEO | 9,000 | $157.03 | Sell | $1,413,270.00 | |
| Jan. 24, 2018 | CEO | 22,500 | $165.00 | Sell | $3,712,500.00 | |
| Jan. 19, 2018 | CEO | 28,099 | $153.70 | Sell | $4,318,816.30 | |
| Jan. 10, 2018 | Director | 2,500 | $145.00 | Sell | $362,500.00 | |
| Dec. 20, 2017 | Director | 925 | $137.25 | Sell | $126,956.25 | |
| Nov. 17, 2017 | VP | 6,559 | $142.63 | Sell | $935,510.17 | |
| Nov. 16, 2017 | Director | 5,000 | $141.71 | Sell | $708,550.00 | |
| Nov. 16, 2017 | CEO | 5,269 | $142.53 | Sell | $750,990.57 | |
| Sept. 5, 2017 | CEO | 5,000 | $130.00 | Sell | $650,000.00 | |
| Aug. 23, 2017 | Director | 2,000 | $127.99 | Sell | $255,980.00 | |
| Aug. 9, 2017 | VP | 18,625 | $126.96 | Sell | $2,364,630.00 | |
| Aug. 9, 2017 | Insider | 6,100 | $127.51 | Sell | $777,811.00 | |
| Aug. 8, 2017 | CEO | 5,483 | $125.00 | Sell | $685,375.00 | |
| June 21, 2017 | CEO | 4,666 | $120.00 | Sell | $559,920.00 | |
| June 9, 2017 | CEO | 12,000 | $114.87 | Sell | $1,378,440.00 | |
| May 12, 2017 | Director | 37,247 | $110.76 | Sell | $4,125,477.72 | |
| May 12, 2017 | Insider | 5,621 | $112.20 | Sell | $630,676.20 | |
| March 20, 2017 | CEO | 4,000 | $109.10 | Sell | $436,400.00 | |
| March 2, 2017 | Insider | 6,879 | $103.39 | Sell | $711,219.81 | |
| Feb. 28, 2017 | Director | 32,000 | $106.35 | Sell | $3,403,200.00 | |
| Nov. 25, 2016 | Director | 18,479 | $107.31 | Sell | $1,982,981.49 | |
| Nov. 18, 2016 | Director | 6,330 | $105.28 | Sell | $666,422.40 | |
| Sept. 22, 2016 | CEO | 3,000 | $117.34 | Sell | $352,020.00 | |
| Sept. 7, 2016 | Director | 1,000 | $115.00 | Sell | $115,000.00 | |
| Sept. 1, 2016 | Director | 1,666 | $105.40 | Sell | $175,596.40 | |
| Aug. 1, 2016 | Director | 1,000 | $137.57 | Sell | $137,570.00 | |
| July 1, 2016 | Director | 1,000 | $121.40 | Sell | $121,400.00 | |
| June 1, 2016 | Director | 1,000 | $117.42 | Sell | $117,420.00 | |
| May 18, 2016 | Director | 334 | $120.50 | Sell | $40,247.00 | |
| May 6, 2016 | Director | 25,000 | $119.20 | Sell | $2,980,000.00 |
Insiders are both buying and selling Ligand Pharmaceuticals Incorporated stock.
The insider traders at Ligand Pharmaceuticals Incorporated are: Matthew W Foehr, John L Higgins, Jason Aryeh, John W Kozarich, Charles S Berkman, Todd C Davis, Bvf Partners L P/Il, Stephen L Sabba, Melanie J Herman, David M Knott, Bvf Partners P/Il, John L Lamattina, David Knott, Nishan M Desilva, Sunil Patel, John Sharp, Charles Berkman, Matthew E Korenberg, Matthew Foehr, Octavio Espinoza, Todd Davis, John Higgins, John Lamattina, John W. Kozarich, Melanie J. Herman, and Andrew Reardon
The most active insider trader at Ligand Pharmaceuticals Incorporated is Matthew W Foehr with 27 trades.
Bvf Partners P/Il has sold the most Ligand Pharmaceuticals Incorporated stock with a total value of $58,156,493.18.
Bvf Partners L P/Il has bought the most Ligand Pharmaceuticals Incorporated stock with a total value of $2,817,728.47.
The most recent insider trade for Ligand Pharmaceuticals Incorporated was on March 5, 2024.
The single biggest insider buy for Ligand Pharmaceuticals Incorporated was from Bvf Partners L P/Il with a total value of $898,794.00 on Dec. 6, 2012.
The single biggest insider sell for Ligand Pharmaceuticals Incorporated was from Bvf Partners P/Il with a total value of $31,214,249.00 on Feb. 20, 2014.